On Friday, C4 Therapeutics Inc (NASDAQ: CCCC) was 3.41% up from the session before settling in for the closing price of $2.05. A 52-week range for CCCC has been $1.09 – $7.36.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -8.92%. When this article was written, the company’s average yearly earnings per share was at -13.82%. With a float of $54.23 million, this company’s outstanding shares have now reached $70.99 million.
Let’s determine the extent of company efficiency that accounts for 110 employees. In terms of profitability, gross margin is 85.25%, operating margin of -292.99%, and the pretax margin is -259.27%.
C4 Therapeutics Inc (CCCC) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward C4 Therapeutics Inc stocks. The insider ownership of C4 Therapeutics Inc is 23.62%, while institutional ownership is 80.33%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.84% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
You can see what C4 Therapeutics Inc (CCCC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.47, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.65 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Looking closely at C4 Therapeutics Inc (NASDAQ: CCCC), its last 5-days average volume was 0.68 million, which is a drop from its year-to-date volume of 1.38 million. As of the previous 9 days, the stock’s Stochastic %D was 14.16%.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 63.78%, which indicates a significant increase from 25.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.23 in the past 14 days, which was higher than the 0.17 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.74, while its 200-day Moving Average is $2.93. However, in the short run, C4 Therapeutics Inc’s stock first resistance to watch stands at $2.21. Second resistance stands at $2.30. The third major resistance level sits at $2.41. If the price goes on to break the first support level at $2.01, it is likely to go to the next support level at $1.90. Now, if the price goes above the second support level, the third support stands at $1.81.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
There are 71,007K outstanding shares of the company, which has a market capitalization of 150.54 million. As of now, sales total 35,580 K while income totals -105,320 K. Its latest quarter income was 7,240 K while its last quarter net income were -26,320 K.
